|
Synonyms: ESK-001 | ESK001
Compound class:
Synthetic organic
Comment: The chemical structure for envudeucitinib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a Janus kinase inhibitor with anti-inflammatory potential. It was later disclosed as an orally bioavailable allosteric TYK2 inhibitor, with company code ESK-001 [1,3]. Envudeucitinib targets the allosteric pseudokinase structural domain (JH2) of TYK2.
|
|
|||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| TYK2 inhibitors target the inflammatory JAK-STAT signalling pathway [4]. This mechanism reduces production of cytokines (such as IL-12, IL-23, and type I interferons (IFN α/β) that drive the pro-inflammatory IL-23/IL-17 axis. Therapeutic doses of TYK2 inhibitors generally have a more favorable safety profile compared to the doses of JAK1-3 inhibitors that are required to achieve therapeutic effects. |